Welcome to BioSeeker Group!

Triple Analysis: Leukemia, Prostate Cancer and Angiogenesis

Additional Information

Published Date Sep 12, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 4344
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Leukemia, Prostate Cancer and Angiogenesis in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Leukemia and Prostate Cancer and by the mechanism/target/effect of Angiogenesis.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Prostate Cancer and Angiogenesis.

    To find out more about Triple Analysis: Leukemia, Prostate Cancer and Angiogenesis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Prostate Cancer and Angiogenesis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Leukemia and Prostate Cancer and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Leukemia
The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part II: Prostate Cancer
The prostate cancer drug report part comprises defined and up to date development strategies for 394 drugs within the portfolio of 222 companies world-wide, from Ceased to Marketed. The report extensively analyses their 227 identified drug targets, organized into 216 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Competitive Handbook towards Personalized Medicine in Prostate Cancer

Part III: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Leukemia
5.1 The Scope of this Report 29
6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443
7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727
8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728
9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129
11 Disclaimer 1130
12 Drug Index 1131
13 Company Index 1140
Figures: Includes 6 Figures
Tables: Includes 253 Tables
Total Number of Pages: 1,147

Part II: Prostate Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Prostate Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (227 Drug Targets) 35-437
7 Emerging New Products to Established Ones: Drug Target Strategies of Prostate Cancer Drugs by their Highest Stage of Development (216 Drug Target Strategies and 394 Drugs) 438-699
8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-748
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Prostate Cancer Drug Pipeline by Investigator (222 Investigators and 394 Drugs) 749-1470
10 Disclaimer 1471
Figures: Includes 8 Figures
Tables: Includes 283 Tables
Total Number of Pages: 1,493

Part III: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

This Report Includes the Following Companies:
3M Pharmaceuticals
4SC
Abbott
Abiogen
Acceleron Pharma
Access
Actinium Pharmaceuticals
Active Biotech
Adherex
Advantagene
Advaxis
Advenchen
AEgera
AEterna Zentaris
Agennix
Agenus
Aida Pharmaceuticals
Alchemia
Alethia Biotherapeutics
Alexion
Alfa Wassermann
Allos Therapeutics
Alnylam
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
American Gene Technology International
Amgen
Amphora
Anavex Life Sciences
AndroBioSys
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisense Pharma
Antisense Therapeutics
Antisoma
Aphios
ApopLogic Pharmaceuticals
Apotex
Aprea
Arana Therapeutics
Arca biopharma
Ardana
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Asahi Kasei Pharma
Ascenta Therapeutics
Ascepion Pharmaceuticals
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
AVI BioPharma
Bavarian Nordic
Baxter International
Bayer
Bellicum Pharmaceuticals
Bio-Path Holdings
BioAlliance Pharma
BioAxone
Biocad
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
BioLineRx
BioMarin
BioNetWorks
BioSante
Biostar
Bioton
Boehringer Ingelheim
Bolder BioTechnology
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Camurus
Cancer Research Technology
CDG Therapeutics
Cel-Sci
Celator Pharmaceuticals
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Cellmid
Celsion
Center of Molecular Immunology
Cephalon
ChemoCentryx
Chemokine Therapeutics
China Sky One Medical
Choongwae
Circadian Technologies
CJ Corp
Clavis Pharma
Cleveland BioLabs
Colby
Cornerstone Pharmaceuticals
Cosmo Bioscience
CSL
Cue Biotech
Curacyte
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytochroma
Cytokinetics
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DiaMedica
Dong-A
Dongkook Pharm
Dyax
ECI
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Endocyte
Ensemble Discovery
EntreMed
Enzon
EpiCept
Epizyme
Erimos
Esperance Pharmaceuticals
Etubics
EUSA Pharma
Exelixis
ExonHit Therapeutics
Ferring
Five Prime Therapeutics
Formula Pharmaceuticals
Galena Biopharma
GammaCan
Gemin X Biotechnologies
Gemin X Pharmaceuticals
Genencor
Genentech
Generex
Genmab
GENova Biotherapeutics
Genovax
Genta
Genzyme
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
GlycoMimetics
Got-a-Gene
GP Pharm
Green Cross
GTx
Hanmi
Harbor BioSciences
Hayashibara
Heber Biotec
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Idera Pharmaceuticals
IDM Pharma
IGF Oncology
IkerChem
ImClone Systems
Immune Pharmaceuticals
Immunocore
ImmunoGen
Immunomedics
ImmuPharma
Incyte Corporation
InDex Pharmaceuticals
Inex
Infinity Pharmaceuticals
Innate Pharma
Innovive
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
Italfarmaco
Ivy Medical Chemicals
Johnson & Johnson
KAI Pharmaceuticals
KaloBios
Kanisa
Karo Bio
Karus Therapeutics
Kinex
Kirin Pharma
Kringle Pharma
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lorus Therapeutics
Mannkind
Marillion Pharmaceuticals
MAT Biopharma
MaxCyte
MaxoCore Pharmaceuticals
Med Discovery
Meda
Medarex
MediGene
MedImmune
Mediolanum
Medivation
Memgen
Menarini
Merck & Co
Merck KGaA
Merrion Pharmaceuticals
Mersana Therapeutics
MethylGene
Micromet
Mojave Therapeutics
Molecular Insight
MolMed
Mologen
Morvus Technology
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurocrine Biosciences
NewSouth Innovations
NIH
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
Novartis
Novelix
Novogen
Noxxon
Oasmia
OncoGenex Pharmaceuticals
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Orion Pharma
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
OXiGENE
Paladin Labs
Pantarhei Bioscience
Pepscan Therapeutics
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmacopeia
Pharmacyclics
PharmaGap
PharmaMar
Pharminox
Philogen
PhiloGene
PIERIS Proteolab
Pierre Fabre
Piramal
Portola Pharmaceuticals
Prochon Biotech
Progen
Progenics Pharmaceuticals
ProMetic Life Sciences
ProNAi Therapeutics
ProStrakan
Protein Sciences
Protgen
PTC Therapeutics
Q Chip
QLT
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
Rexahn
Rigel
Salzburg Therapeutics
Samyang
Sangamo BioSciences
Sanofi
Sanofi-Aventis
Santaris Pharma
Sapphire Therapeutics
Sareum
SBI Biotech
SBIO
Scancell
SciClone Pharmaceuticals
Seattle Genetics
SeleXel
Semafore Pharmaceuticals
Sepal Pharma
Serometrix
Servier
SGX Pharmaceuticals
Shenogen
Shionogi
Shire
Sidus
Siena Biotech
Simcere Pharmaceuticals
Soligenix
Sophiris Bio
Southern Research Institute
Spear Therapeutics
Spirogen
SRI International
Stainwei Biotech
Stemline Therapeutics
SuperGen
Supratek Pharma
Swedish Orphan Biovitrum
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Synageva BioPharma
SynDevRx
Synta Pharmaceuticals
Syntrix
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Targa Therapeutics
TargeGen
Tau Therapeutics
TeGenero
Teva
Thallion Pharmaceuticals
Therion Biologics
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
Tokai Pharmaceuticals
ToolGen
TopoTarget
Tracon Pharmaceuticals
Transgene
Trion Pharma
Twinstrand Therapeutics
UCB
Unigene
United Biomedical
Valeant
Vaxon Biotech
VBL Therapeutics
Velacor Therapeutics
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
Viralytics
ViroTarg
VM Discovery
XBiotech
Xencor
Xerion
Xoma
Yamasa Corporation
YM BioSciences
Zenyaku Kogyo
Zydus Cadila
A Shortlist of Drugs Included are:
A6
abarelix
abiraterone acetate
ABT-510
adecatumumab
aderbasib
AEZS-108
afatinib
aflibercept
alemtuzumab
ALT-801
alvocidib
AMG-386
amonafide dihydrochloride
amonafide malate
amsacrine
Angiozyme
apatinib
APC-100
APR-246
ARC-100
ARQ-197
atrasentan
AVX-701
axitinib
bafetinib
barasertib
belinostat
bevacizumab
BIBF-1120
bicalutamide
bisantrene
BMS-690514
BMS-777607
BMS-936558
bortezomib
bosutinib
BP-GMAX-CD1
brivanib alaninate
buserelin
Cabozantinib
carlumab
cediranib
celecoxib
cetuximab
cilengitide
cixutumumab
cladribine
clofarabine
CSF-GM
custirsen
cytarabine ocfosfate
cytarabine, injectable
danusertib
dasatinib
daunorubicin
DCVax-prostate
decitabine
degarelix
denosumab
deslorelin
DI-17E6
docetaxel
dovitinib lactate
doxercalciferol
doxorubicin
dutasteride
E-75
E-7820
elacytarabine
endostatin
ENMD-2076
enocitabine
entinostat
enzastaurin hydrochloride
estramustine phosphate sodium
ethinyl estradiol sulfonate
everolimus
Exherin
figitumumab
flutamide
foretinib
fosbretabulin tromethamine
fulvestrant
gataparsen
GDC-0980
gefitinib
gemtuzumab ozogamicin
GliaAtak
goserelin
GT-111
GTx-758
GVAX
GVX-3322
GX-301
HBP-347
HE-3235
histamine dihydrochloride
histrelin
icrucumab
idarubicin
idronoxil
imatinib mesilate
inecalcitol
INSM-18
interferon
interferon (alpha-N1)
interferon (alpha)
interferon (alpha2)
interferon (alpha2a)
interferon (alpha2b)
interferon (alpha2c)
interferon (gamma)
interferon alpha-2b
interleukins
intetumumab
ipilimumab
IPP-204106
irosustat
ispinesib mesylate
JI-101
KX2-391
lapatinib ditosylate
lenvatinib
lestaurtinib
leucine-doxorubicin
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
leuprorelin acetate
linifanib
LIP-131I
LipoVIL12
litronesib
LOR-2040
LOR-2501
lumiliximab
LY-2275796
MCS-110
MDV-3100
MGCD-265
midostaurin
mitoxantrone
MLN-8237
motesanib diphosphate
muparfostat (IV)
Nab-docetaxel
nadroparin
NGR-TNF
nilotinib
nilutamide
nimotuzumab
obinutuzumab
oblimersen sodium
ofatumumab
OGX-427
olaparib
olaratumab
ON-01910
orteronel
OTS-102
ozarelix
paclitaxel
paclitaxel polyglumex
PancAtak
panitumumab
panobinostat
pazopanib hydrochloride
PCI-27483
pegdinetanib
peginterferon alfa-2b
pentostatin
perifosine
pertuzumab
PF-4856884
plitidepsin
PLX-3397
ponatinib
ProstAtak
PROSTVAC
PRX-302
PTC-299
PX-866
quarfloxacin
quinacrine
R-(-)-gossypol
RAF-265
ramucirumab
razoxane
regorafenib
retaspimycin
rhIFN-alpha
ridaforolimus
rilotumumab
rituximab
romidepsin
ruxolitinib
sagopilone
sargramostim
SB-939
siltuximab
sipuleucel-T
sirolimus
sobuzoxane
sorafenib tosylate
SU-6668
sunitinib malate
TAK-448
talactoferrin alfa
tamibarotene
tandutinib
TAS-102
tasquinimod
TB-403
telatinib
temsirolimus
Tenarad
teniposide
thymalfasin
tipifarnib
tivozanib
TOK-001
toremifene citrate
TRC-105
tremelimumab
trilostane
triptorelin
TroVax
TS-1
tucotuzumab celmoleukin
vandetanib
vismodegib
volociximab
vosaroxin
XL-184
XL-647
YM-155
zibotentan
zorubicin

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Prostate Cancer and Angiogenesis.
    To find out more about Triple Analysis: Leukemia, Prostate Cancer and Angiogenesis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Prostate Cancer and Angiogenesis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Pancreatic Cancer, Apoptosis and Angiogenesis
This triple analysis focuses on cancer drug development strategies in Pancreatic Cancer and by the two mechanism/target/effect areas of Apoptosis and Angiogenesis. Learn More


Triple Analysis: Breast Cancer, Melanoma and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Melanoma and by the mechanism/target/effect of Angiogenesis. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Lymphoma, Apoptosis and Angiogenesis
This triple analysis focuses on cancer drug development strategies in Lymphoma and by the two mechanism/target/effect areas of Apoptosis and Angiogenesis. Learn More


The Latest Sales Figures in Oncology Drug Pipeline Update
BioSeeker Group have identified 46 companies plus partners who are today developing 114 The Latest Sales Figures in Oncology drugs in 1477 developmental projects in cancer across 113 different targets. In addition, there are 2 suspended drugs and another 27 drugs where development has been ceased. Learn More